Iconic Libertarian Activist Optimistic Following Diagnosis Of Late-Stage Cancer

in News

Justin Raimondo, a prominent libertarian activist of many decades, was recently diagnosed with late-stage adenocaricinoma cancer that he is treating with experimental medication.

“However, Keytruda – recently approved by the Food and Drug Administration – for cases like mine, has proved to be a godsend for many patients previously thought hopeless. While the results are preliminary, they are hopeful: it looks like I have the key mutation that gives Keytruda one up on this terrible disease,” Raimondo said.

Raimondo has bonafides within the libertarian movement that few can duplicate. In addition to being the editorial director of a successful non-interventionist publication for many years, Raimondo was a cherished colleague of the late Murray N. Rothbard, the preeminent Austrian economist largely credited for establishing the modern libertarian movement.

Raimondo has written several books as well including, “An Enemy of the State: The Life of Murray N. Rothbard” and “Reclaiming the American Right: The Lost Legacy of the Conservative Movement.” Additionally, Raimondo has won favor with anti-establishment conservatives such as Ann Coulter and Pat Buchanan while refusing to jeopardize the pure libertarian message.

“I can’t help but think that this illness is a temporary inconvenience that can and will be overcome. I have no doubt that some days I will be incapacitated and unable to write, however I intend to write as much as I can, whenever I can,” Raimondo said.

Raimondo urges people to support his life’s work during his time of need because regardless of how his battle against cancer turns out, the military-industrial complex will still need to be exposed and defeated.

“No matter what happens to me, Antiwar.com will continue, just as it always has, thanks to our hardworking and ever-faithful staff,” Raimondo said. “But we can’t do it without your financial support.”

1 Comment

Leave a Reply

Your email address will not be published.

Latest from News

Go to Top

Thanks for visiting our site! Stay in touch with us by subscribing to our newsletter. You will receive all of our latest updates, articles, endorsements, interviews, and videos direct to your inbox.